Boric Acid Treatment Strengthens the Cytotoxic Effect of Sorafenib on Triple Negative Breast Cancer Cell Lines

dc.contributor.authorKahraman, Erkan
dc.contributor.authorGöker, Erdem
dc.date.accessioned2024-08-25T18:45:24Z
dc.date.available2024-08-25T18:45:24Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractIn recent years, it has been demonstrated that combinational therapies have shown promising results in the treatment of triple negative breast cancer. However, the effect of the sequential combination of sorafenib with boric acid on cell viability in triple negative breast cancer cell lines is unknown. Thus, the present study aims to investigate the effects of sequential treatment of boric acid and sorafenib on cell viability in triple negative breast cancer cell lines. MDA-MB-231 cells were used in our study. Sorafenib was treated to the cells at a dose range of 0.5-16µM, and boric acid at 1-160mM. Changes in cell viability were determined using by MTT analysis at 24,48 and 72 hours. Cell viability decreased statistically significantly at 4µM and above doses of sorafenib, and 5mM and above doses of boric acid (pen_US
dc.identifier.doi10.18466/cbayarfbe.1201068
dc.identifier.endpage141en_US
dc.identifier.issn1305-130X
dc.identifier.issn1305-1385
dc.identifier.issue2en_US
dc.identifier.startpage137en_US
dc.identifier.trdizinid1183725en_US
dc.identifier.urihttps://doi.org/10.18466/cbayarfbe.1201068
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1183725
dc.identifier.urihttps://hdl.handle.net/11454/101548
dc.identifier.volume19en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofCelal Bayar Üniversitesi Fen Bilimleri Dergisien_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.titleBoric Acid Treatment Strengthens the Cytotoxic Effect of Sorafenib on Triple Negative Breast Cancer Cell Linesen_US
dc.typeArticleen_US

Dosyalar